Paul M. Rivard discusses the CAFC’s decision to grant a rehearing in Tafas v. Doll.

Mr. Rivard comments on the Fed Circuit’s decision to rehear Tafas v. Doll in FDA News and Managing Intellectual Property.  Mr. Rivard addresses how this decision will impact the pharmaceutical industry.

Posted: July 20, 2009

Contact Banner Witcoff Share on LinkedIn View this page as a pdf Share on Twitter Email this page Print this page